These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8036043)

  • 1. Protection provided by Haemophilus influenzae type b conjugate vaccines in Los Angeles County: a case-control study.
    Vadheim CM; Greenberg DP; Eriksen E; Hemenway L; Christenson P; Ward B; Mascola L; Ward JI
    Pediatr Infect Dis J; 1994 Apr; 13(4):274-80. PubMed ID: 8036043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective efficacy of Haemophilus influenzae type b polysaccharide and conjugate vaccines in children 18 months of age and older.
    Greenberg DP; Vadheim CM; Bordenave N; Ziontz L; Christenson P; Waterman SH; Ward JI
    JAMA; 1991 Feb; 265(8):987-92. PubMed ID: 1992212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccine failures after primary immunisation with Haemophilus influenzae type-b conjugate vaccine without booster.
    Booy R; Heath PT; Slack MP; Begg N; Moxon ER
    Lancet; 1997 Apr; 349(9060):1197-202. PubMed ID: 9130940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postlicensure effectiveness of the Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer-membrane protein complex conjugate vaccine among Navajo children.
    Harrison LH; Tajkowski C; Croll J; Reid R; Hu D; Brenneman G; Weatherholtz RC; Santosham M
    J Pediatr; 1994 Oct; 125(4):571-6. PubMed ID: 7931875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization with oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine on a large health maintenance organization population: extended follow-up and impact on Haemophilus influenzae disease epidemiology. The Kaiser Permanente Pediatric Vaccine Study Group.
    Black SB; Shinefield HR
    Pediatr Infect Dis J; 1992 Aug; 11(8):610-3. PubMed ID: 1523069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Haemophilus influenzae type b vaccines in Massachusetts children 18 to 59 months of age.
    Loughlin AM; Marchant CD; Lett S; Shapiro ED
    Pediatr Infect Dis J; 1992 May; 11(5):374-9. PubMed ID: 1630857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postlicensure surveillance for Haemophilus influenzae type b invasive disease after use of Haemophilus influenzae type b oligosaccharide CRM197 conjugate vaccine in a large defined United States population: a four-year eight-month follow-up.
    Shinefield HR; Black S
    Pediatr Infect Dis J; 1995 Nov; 14(11):978-81. PubMed ID: 8584366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eradication of Haemophilus influenzae type b disease in southern California. Kaiser-UCLA Vaccine Study Group.
    Vadheim CM; Greenberg DP; Eriksen E; Hemenway L; Bendana N; Mascola L; Ward JI
    Arch Pediatr Adolesc Med; 1994 Jan; 148(1):51-6. PubMed ID: 8143010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haemophilus influenzae type b conjugate vaccines: a review of efficacy data.
    Heath PT
    Pediatr Infect Dis J; 1998 Sep; 17(9 Suppl):S117-22. PubMed ID: 9781743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody concentration and clinical protection after Hib conjugate vaccination in the United Kingdom.
    Heath PT; Booy R; Azzopardi HJ; Slack MP; Bowen-Morris J; Griffiths H; Ramsay ME; Deeks JJ; Moxon ER
    JAMA; 2000 Nov; 284(18):2334-40. PubMed ID: 11066183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group.
    Black SB; Shinefield HR; Fireman B; Hiatt R; Polen M; Vittinghoff E
    Pediatr Infect Dis J; 1991 Feb; 10(2):97-104. PubMed ID: 2062621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-benefit analysis for the use of Haemophilus influenzae type b conjugate vaccine in Santiago, Chile.
    Levine OS; Ortiz E; Contreras R; Lagos R; Vial P; Misraji A; Ferreccio C; Espinoza C; Adlerstein L; Herrera P
    Am J Epidemiol; 1993 Jun; 137(11):1221-8. PubMed ID: 8322763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in US children aged 18-59 months. Haemophilus Influenzae Vaccine Efficacy Study Group.
    Wenger JD; Pierce R; Deaver KA; Plikaytis BD; Facklam RR; Broome CV
    Lancet; 1991 Aug; 338(8764):395-8. PubMed ID: 1678080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, immunogenicity, and efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b vaccine in a United States population: possible implications for optimal use.
    Black SB; Shinefield HR; Fireman B; Hiatt R
    J Infect Dis; 1992 Jun; 165 Suppl 1():S139-43. PubMed ID: 1588149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody response of Navajo children primed with PRP-OMP vaccine to booster doses of PRP-OMP vs. HbOC vaccine.
    Reid R; Santosham M; Croll J; Thompson C; Newcomer W; Siber GR
    Pediatr Infect Dis J; 1993 Oct; 12(10):812-5. PubMed ID: 8284116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interchangeability of conjugated Haemophilus influenzae type b vaccines in infants.
    Anderson EL; Decker MD; Englund JA; Edwards KM; Anderson P; McInnes P; Belshe RB
    JAMA; 1995 Mar; 273(11):849-53. PubMed ID: 7869554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haemophilus influenzae type B epiglottitis after immunization with HbOC conjugate vaccine.
    Keyser JS; Derkay CS
    Am J Otolaryngol; 1994; 15(6):436-43. PubMed ID: 7872480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Continued shortage of Haemophilus influenzae Type b (Hib) conjugate vaccines and potential implications for Hib surveillance--United States, 2008.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2008 Nov; 57(46):1252-5. PubMed ID: 19023262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenocity of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C-tetanus-toxoid conjugate vaccine in healthy Chinese children aged 6 months to 5 years old.
    Hu JL; Tao H; Li JX; Dai WM; Song B; Sun JF; Liu P; Tang J; Liu WY; Wang SY; Zhu FC
    Hum Vaccin Immunother; 2015; 11(5):1120-8. PubMed ID: 25833163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and antibody persistence following Haemophilus influenzae type b conjugate or pneumococcal polysaccharide vaccines given before pregnancy in women of childbearing age and their infants.
    Santosham M; Englund JA; McInnes P; Croll J; Thompson CM; Croll L; Glezen WP; Siber GR
    Pediatr Infect Dis J; 2001 Oct; 20(10):931-40. PubMed ID: 11642626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.